Oruka advances ORKA-001/002 with multiple 2026–2027 catalysts and solid cash
Aug 10, 2026, 7:11 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The company is advancing two co-lead programs with multiple near-term catalysts (EVERLAST-A Week 28, ORCA-SURGE Week 16) and a Phase 3 program on the horizon (1H27). A strong cash position ($1.1B) plus new data readouts and new clinic entry for ORKA-004 could re-rate the stock if readouts meet or exceed expectations, despite dilution from a $700M offering in April 2026.
AI summary
What happened, with direct paths to the underlying reporting
Oruka reported Q2 2026 results with a corporate update highlighting key catalysts for ORKA-001 and ORKA-002. Near-term data readouts include EVERLAST-A Week 28 by end-3Q26 and Week 16 results for ORCA-SURGE in 1Q2027, with ORKA-004 entering clinic in 4Q2026. The company also reaffirmed a $1.1B cash balance, supporting operations through a potential ORKA-001 BLA filing and continued ORKA-002 development, shaping a favorable risk-reward in the 2026–2027 window.
EVERLAST-A Week 28 data due end of 3Q 2026. 52-week data for all participants in December 2026.
ORKA-001 Phase 3 program expected to begin in 1H 2027.
ORCA-SURGE Week 16 data moved to 1Q 2027; ORCA-SPLASH HS trial initiated.
ORKA-004 TL1A antibody to enter clinic in 4Q 2026.
Cash, cash equivalents and marketable securities of $1.1 billion; funds through BLA filing.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Oruka Therapeutics reported strong efficacy for its ORKA-001 treatment, achieving 63.5% complete skin clearance among participants, with favorable safety data. The stock surged 39…
